Liver Decompensation With Atezolizumab–Bevacizumab in Hepatocellular Carcinoma

The study on atezolizumab–bevacizumab treatment for advanced or unresectable hepatocellular carcinoma (HCC) provides valuable insights into liver decompensation as a key clinical consideration. Below is a detailed analysis of liver decompensation in this context:

Incidence of Liver Decompensation

• Approximately one-quarter of patients developed liver decompensation during treatment with atezolizumab–bevacizumab.
• Decompensation events were more frequent in patients with Child Pugh B liver function compared to those with Child Pugh A.

Common Manifestations of Liver Decompensation

The most frequent clinical presentations of liver decompensation observed during therapy included:

1. Ascites (fluid accumulation in the abdominal cavity),

2. Jaundice (yellowing of the skin and eyes due to elevated bilirubin),

3. Hepatic encephalopathy (brain dysfunction caused by liver failure).

Risk Factors for Liver Decompensation

• Baseline liver function is a critical determinant. Patients with worse liver function (e.g., Child Pugh B or ALBI grade 3) were at higher risk of decompensation.
• Portal hypertension, identified at baseline, was an independent risk factor for liver decompensation during therapy.

Time to Decompensation

• The study introduced time to decompensation as a novel and clinically relevant safety endpoint. This metric is important for assessing the timing and progression of liver-related complications during treatment.

Impact of Liver Decompensation on Treatment and Survival

1. Resumption of Therapy:

• Despite liver decompensation, over 40% of patients were able to resume atezolizumab–bevacizumab therapy.
• Patients who restarted treatment after decompensation demonstrated overall survival outcomes comparable to those who never experienced decompensation.

2. Discontinuation of Therapy:

• Permanent discontinuation of treatment after liver decompensation was associated with markedly worse survival outcomes.

3. Reversibility of Liver Function:

• Some patients with Child Pugh B liver function experienced an improvement in liver function, reverting to Child Pugh A during treatment.
• This suggests that liver decompensation does not always signify irreversible liver failure or treatment failure.

Clinical Implications

• Liver decompensation should not automatically be considered treatment failure or disease progression. Instead, it requires careful evaluation and management.
• Multidisciplinary hepato-oncologic care is essential for the safe continuation or resumption of therapy in patients experiencing liver decompensation.
• Patients with mild-to-moderate liver dysfunction (e.g., Child Pugh B) should not be excluded from atezolizumab–bevacizumab treatment, as meaningful outcomes can still be achieved.

Prognostic Stratification

• The albumin–bilirubin (ALBI) score was found to be a stronger tool for prognostic stratification than the Child Pugh class.
• Patients with ALBI grade 3 had significantly poorer survival and a higher risk of liver decompensation compared to those with better ALBI grades.

Conclusion

Liver decompensation is a notable complication during atezolizumab–bevacizumab therapy for HCC, particularly in patients with impaired baseline liver function. However, it should not preclude treatment continuation or resumption, as many patients achieve meaningful survival outcomes. Multidisciplinary care and individualized management strategies are crucial for optimizing outcomes in these patients.